Key facts
- It has raised $450K across 1 recorded rounds; the latest was Seed Round ($450K) in Nov 2023.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Immorta Bio
Funding rounds
1 roundsAbout Immorta Bio
Developer of a scientific longevity platform designed to reverse aging and treat age-related diseases. The company offers senolytic immunotherapy that targets senescent cells and personalized cellular rejuvenation technologies using organ-specific progenitor and mesenchymal stem cells, enabling patients and clinicians to address aging-related conditions through immunotherapy and regenerative medicine.
- Sector
- Healthcare
- HQ
- Aventura, FL, United States
- Founded
- 2023
- Employees
- 8
- Website
- immortabio.com/
- Ownership
- Privately Held (backing)
Immorta Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immorta Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immorta Bio in its N-PORT filings yet. We sweep new filings monthly.